Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPLAT1: Autologous iPS Cell-Derived Platelet Transfusion in Thrombocytopenia
jRCTa050190117Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2019
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of MEG-002 in aplastic anemia and Thrombocytopenia, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Safety of autologous iPS cell-derived platelet transfusion. Started May 2019; status: completed.
02
Drugs
MEG-002
03
Conditions
aplastic anemiaThrombocytopenia
Beyond the preview
Go deeper on jRCTa050190117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTa050190117.